Translational medicine and the value of biomarker qualification
- PMID: 20811041
- DOI: 10.1126/scitranslmed.3001040
Translational medicine and the value of biomarker qualification
Abstract
The gap between development of exploratory biomarkers and their acceptance in drug development and regulatory review is a hurdle in the development of better therapies. The U.S. Food and Drug Administration has developed a regulatory process for biomarker qualification to accelerate the process by which new biomarkers are integrated in the development of therapies.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous
